Figure 2. Proportion of Medicare Fee-for-Service Beneficiaries With Newly Diagnosed Metastatic Non–Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC) Who Received Molecular Testing and Types of Therapy Used for First-line Treatment by Quarter, 2015 to 2019.

C and D, Includes only patients with Part D coverage.